Innovative proteomics for the discovery of systemically accessible cancer biomarkers suitable for imaging and targeted therapies

American Journal of Pathology

Volumn 178, Issue 1, 2011, Pages 12-18

  Turtoi, Andrei ^a   De Pauw, Edwin ^a   Castronovo, Vincent ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYTOTOXIC AGENT; GEMTUZUMAB OZOGAMICIN; IBRITUMOMAB TIUXETAN; LIGAND; MONOCLONAL ANTIBODY L19 I 131; RITUXIMAB; TOSITUMOMAB I 131; TUMOR MARKER; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; AMINO ACID SEQUENCE; ANTIBODY AFFINITY; B CELL LYMPHOMA; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER TISSUE; CELL MEMBRANE; COLON CARCINOMA; CONCENTRATION (PARAMETERS); EXTRACELLULAR MATRIX; FOLLICULAR LYMPHOMA; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HIGH THROUGHPUT SCREENING; HODGKIN DISEASE; HUMAN; ION CYCLOTRON RESONANCE MASS SPECTROMETRY; KIDNEY CANCER; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MOLECULAR IMAGING; MOLECULARLY TARGETED THERAPY; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN TARGETING; PROTEOMICS; REVIEW; TARGET CELL DESTRUCTION;

EID: 79251490378     PISSN: 00029440     EISSN: 15252191     Source Type: Journal    
DOI: 10.1016/j.ajpath.2010.08.004     Document Type: Review

References (49)

1. Strebhardt K, Ullrich A: Paul Ehrlich's magic bullet concept: 100 years of progress. Nat Rev Cancer 2008, 8:473-480 (Pubitemid 351752547)
2. Kischel P, Waltregny D, Castronovo V: Identification of accessible human cancer biomarkers using ex vivo chemical proteomic strategies. Expert Rev Proteomics 2007, 4:727-739 (Pubitemid 350261439)
3. Rybak JN, Trachsel E, Scheuermann J, Neri D: Ligand-based vascular targeting of disease. Chem Med Chem 2007, 2:22-40
4. Mantovani A: Role of inflammatory cells and mediators in tumor invasion and metastasis. Cancer Metastasis Rev 2010, 29:241
5. Dijkers EC, Kosterink JG, Rademaker AP, Perk LR, van Dongen GA, Bart J, de Jong JR, de Vries EG, Lub-de Hooge MN: Development and characterization of clinical-grade 89Zr-trastuzumab for HER2/neu immunoPET imaging. J Nucl Med 2009, 50:974-981
6. Perk LR, Stigter-van Walsum M, Visser GW, Kloet RW, Vosjan MJ, Leemans CR, Giaccone G, Albano R, Comoglio PM, van Dongen GA: Quantitative PET imaging of Met-expressing human cancer xenografts with 89Zr-labelled monoclonal antibody DN30. Eur J Nucl Med Mol Imaging 2008, 35:1857-1867
7. Duong HK, Sekeres MA: Targeted treatment of acute myeloid leukemia in older adults: role of gemtuzumab ozogamicin. Clin Interv Aging 2009, 4:197-205
8. Johnston PB, Bondly C, Micallef IN: Ibritumomab tiuxetan for non-Hodgkin's lymphoma. Expert Rev Anticancer Ther 2006, 6:861-869
9. Smith S, Sweetenham JW: Iodine 131 tositumomab in the treatment of non-Hodgkin's lymphoma. Future Oncol 2007, 3:255-262
10. Kaspar M, Zardi L, Neri D: Fibronectin as target for tumor therapy. Int J Cancer 2006, 118:1331-1339
11. Borsi L, Balza E, Carnemolla B, Sassi F, Castellani P, Berndt A, Kosmehl H, Biro A, Siri A, Orecchia P, Grassi J, Neri D, Zardi L: Selective targeted delivery of TNFalpha to tumor blood vessels. Blood 2003, 102:4384-4392 (Pubitemid 37494099)
12. Tijink BM, Neri D, Leemans CR, Budde M, Dinkelborg LM, Stigter-van Walsum M, Zardi L, van Dongen GA: Radioimmunotherapy of head and neck cancer xenografts using 131I-labeled antibody L19-SIP for selective targeting of tumor vasculature. J Nucl Med 2006, 47:1127-1235
13. Sauer S, Erba PA, Petrini M, Menrad A, Giovannoni L, Grana C, Hirsch B, Zardi L, Paganelli G, Mariani G, Neri D, Dürkop H, Menssen HD: Expression of the oncofetal ED-B-containing fibronectin isoform in hematologic tumors enables ED-B-targeted 131I-L19SIP radioimmunotherapy in Hodgkin lymphoma patients. Blood 2009, 113:2265-2274
14. Brack SS, Silacci M, Birchler M, Neri D: Tumor-targeting properties of novel antibodies specific to the large isoform of tenascin-C. Clin Cancer Res 2006, 12:3200-3208 (Pubitemid 43837370)
15. Silacci M, Brack SS, Späth N, Buck A, Hillinger S, Arni S, Weder W, Zardi L, Neri D: Human monoclonal antibodies to domain C of tenascin-C selectively target solid tumors in vivo. Protein Eng Des Sel 2006, 19:471-478
16. Berndt A, Anger K, Richter P, Borsi L, Brack S, Silacci M, Franz M, Wunderlich H, Gajda M, Zardi L, Neri D, Kosmehl H: Differential expression of tenascin-C splicing domains in urothelial carcinomas of the urinary bladder. J Cancer Res Clin Oncol 2006, 132:537-546
17. Anderson NL, Anderson NG, Pearson TW, Borchers CH, Paulovich AG, Patterson SD, Gillette M, Aebersold R, Carr SA: A human proteome detection and quantitation project. Mol Cell Proteomics 2009, 8:883-886
18. Wang Y, Seneviratne J. Biomarker discovery in clinical proteomics: strategies for exposing low abundant proteins. Current Proteomics 2008, 5:104-114 (Pubitemid 351988581)
19. Righetti PG, Boschetti E, Lomas L, Citterio A: Protein Equalizer Technology: the quest for a "democratic proteome." Proteomics 20066:3980-3992
20. Emmert-Buck MR, Bonner RF, Smith PD, Chuaqui RF, Zhuang Z, Goldstein SR, Weiss RA, Liotta LA: Laser capture microdissection. Science 1996, 274:998-1001
21. Waanders LF, Chwalek K, Monetti M, Kumar C, Lammert E, Mann M: Quantitative proteomic analysis of single pancreatic islets. Proc Natl Acad Sci U S A 2009, 106:18902-18907
22. Tan S, Tan HT, Chung MC: Membrane proteins and membrane proteomics. Proteomics 2008, 8:3924-3932
23. Rybak JN, Scheurer SB, Neri D, Elia G: Purification of biotinylated proteins on streptavidin resin: a protocol for quantitative elution. Proteomics 2004, 4:2296-2299
24. Rybak JN, Ettorre A, Kaissling B, Giavazzi R, Neri D, Elia G: In vivo protein biotinylation for identification of organ-specific antigens accessible from the vasculature. Nat Methods 2005, 2:291-298
25. Castronovo V, Waltregny D, Kischel P, Roesli C, Elia G, Rybak JN, Neri D: A chemical proteomics approach for the identification of accessible antigens expressed in human kidney cancer. Mol Cell Proteomics 2006, 5:2083-2091
26. Conrotto P, Roesli C, Rybak J, Kischel P, Waltregny D, Neri D, Castronovo V: Identification of new accessible tumor antigens in human colon cancer by ex vivo protein biotinylation and comparative mass spectrometry analysis. Int J Cancer 2008, 123:2856-2864
27. Castronovo V, Kischel P, Guillonneau F, de Leval L, Deféchereux T, De Pauw E, Neri D, Waltregny D: Identification of specific reachable molecular targets in human breast cancer using a versatile ex vivo proteomic method. Proteomics 2007, 7:1188-1196
28. Roesli C, Mumprecht V, Neri D, Detmar M: Identification of the surface-accessible, lineage-specific vascular proteome by two-dimensional peptide mapping. FASEB J 2008, 22:1933-1944
29. Kischel P, Guillonneau F, Dumont B, Bellahcène A, Stresing V, Clézardin P, De Pauw EA, Castronovo V: Cell membrane proteomic analysis identifies proteins differentially expressed in osteotropic human breast cancer cells. Neoplasia 2008, 10:1014-1020
30. Brooks SA: Strategies for analysis of the glycosylation of proteins: current status and future perspectives. Mol Biotechnol 2009, 43: 76-88
31. Zhang H, Li XJ, Martin DB, Aebersold R: Identification and quantification of N-linked glycoproteins using hydrazide chemistry, stable isotope labeling and mass spectrometry. Nature Biotechnol 2003, 21:660-666
32. Tian Y, Zhou Y, Elliott S, Aebersold R, Zhang H: Solid-phase extraction of N-linked glycopeptides. Nat Protoc 2007, 2:334-339
33. Whelan SA, Lu M, He J, Yan W, Saxton RE, Faull KF, Whitelegge JP, Chang HR: Mass spectrometry (LC-MS/MS) site-mapping of N-glycosylated membrane proteins for breast cancer biomarkers. J Proteome Res 2009, 8:4151-4160
34. Arcinas A, Yen TY, Kebebew E, Macher BA: Cell surface and secreted protein profiles of human thyroid cancer cell lines reveal distinct glycoprotein patterns. J Proteome Res 2009, 8:3958-3968
35. Cao J, Shen C, Wang H, Shen H, Chen Y, Nie A, Yan G, Lu H, Liu Y, Yang P: Identification of N-glycosylation sites on secreted proteins of human hepatocellular carcinoma cells with a complementary proteomics approach. J Proteome Res 2009, 8:662-672
36. Chen R, Jiang X, Sun D, Han G, Wang F, Ye M, Wang L, Zou H: Glycoproteomics analysis of human liver tissue by combination of multiple enzyme digestion and hydrazide chemistry. J Proteome Res 2009, 8:651-661
37. Rajcevic U, Niclou SP, Jimenez CR: Proteomics strategies for target identification and biomarker discovery in cancer. Front Biosci 2009, 14:3292-3303
38. Ahmed FE: Sample preparation and fractionation for proteome analysis and cancer biomarker discovery by mass spectrometry. J Sep Sci 2009, 32:771-798
39. Patton WF: Detection technologies in proteome analysis. J Chromatogr B Analyt Technol Biomed Life Sci 2002, 771:3-31
40. Heeren RM, Smith DF, Stauber J, Kükrer-Kaletas B, MacAleese L: Imaging mass spectrometry: hype or hope? J Am Soc Mass Spectrom 2009, 20:1006-1014
41. Diamandis EP: Mass spectrometry as a diagnostic and a cancer biomarker discovery tool: opportunities and potential limitations. Mol Cell Proteomics 2004, 3:367-378
42. Knochenmuss R: Ion formation mechanisms in UV-MALDI. Analyst 2006, 131:966-986
43. Kebarle P, Verkerk UH: Electrospray: from ions in solution to ions in the gas phase, what we know now. Mass Spectrom Rev 2009, 28: 898-917
44. Medzihradszky KF: Peptide sequence analysis. Methods Enzymol 2005, 402:209-244
45. Demeure K, Quinton L, Gabelica V, De Pauw E: Rational selection of the optimum MALDI matrix for top-down proteomics by in-source decay. Anal Chem 2007, 79:8678-8685
46. Wiesner J, Premsler T, Sickmann A: Application of electron transfer dissociation (ETD) for the analysis of posttranslational modifications. Proteomics 2008, 8:4466-4483
47. Aebersold R, Mann M: Mass spectrometry-based proteomics. Nature 2003, 422:198-207
48. Nesvizhskii AI, Vitek O, Aebersold R: Analysis and validation of proteomic data generated by tandem mass spectrometry. Nat Methods 2007, 4:787-797 (Pubitemid 350055575)
49. Schiess R, Wollscheid B, Aebersold R: Targeted proteomic strategy for clinical biomarker discovery. Mol Oncol 2009, 3: 33-44